Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial.
第一作者:
Martin,Reck
第一单位:
Airway Research Center North, German Center for Lung Research, LungClinic, Grosshansdorf, Germany. Electronic address: m.reck@lungenclinic.de.
作者:
主题词
人类(Humans);癌, 非小细胞肺(Carcinoma, Non-Small-Cell Lung);肺肿瘤(Lung Neoplasms);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);男(雄)性(Male);女(雌)性(Female);中年人(Middle Aged);老年人(Aged);成年人(Adult);老年人, 80以上(Aged, 80 and over)
DOI
10.1016/j.ejca.2024.114296
PMID
39270380
发布时间
2024-09-30
- 浏览0
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文